SfN 2025 – LRRK2 Degrader Discovery: A High-Throughput Direct-to-Biology Screening Platform

Accelerating CNS Drug Discovery with a Direct-to-Biology (D2B) Platform

Parkinson’s Disease (PD) is a growing global concern, with LRRK2 emerging as a key therapeutic target. In this study, we showcase a novel high-throughput platform to discover potent degraders against LRRK2 kinase, offering a valuable alternative to traditional kinase inhibition.

Our flexible and scalable direct-to-biology (D2B) approach enabled rapid synthesis and evaluation of bifunctional LRRK2 degraders, identifying several compounds with nanomolar potency, ready for validation in neurologically relevant systems.

👉 Download the free poster to explore how our D2B platform can be applied to neurodegenerative drug discovery beyond LRRK2.